Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.77
SNTA's Cash to Debt is ranked higher than
61% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. SNTA: 3.77 )
SNTA' s 10-Year Cash to Debt Range
Min: 2.27   Max: No Debt
Current: 3.77

F-Score: 3
Z-Score: -7.69
M-Score: -4.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -183.72
SNTA's ROE (%) is ranked lower than
55% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. SNTA: -183.72 )
SNTA' s 10-Year ROE (%) Range
Min: -320.7   Max: 317.48
Current: -183.72

-320.7
317.48
ROA (%) -94.74
SNTA's ROA (%) is ranked lower than
52% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. SNTA: -94.74 )
SNTA' s 10-Year ROA (%) Range
Min: -111.95   Max: 161.7
Current: -94.74

-111.95
161.7
ROC (Joel Greenblatt) (%) -5638.06
SNTA's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. SNTA: -5638.06 )
SNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5638.06   Max: 1993.56
Current: -5638.06

-5638.06
1993.56
Revenue Growth (%) -100.00
SNTA's Revenue Growth (%) is ranked lower than
54% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. SNTA: -100.00 )
SNTA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 164.5
Current: -100

0
164.5
EBITDA Growth (%) 12.20
SNTA's EBITDA Growth (%) is ranked higher than
81% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. SNTA: 12.20 )
SNTA' s 10-Year EBITDA Growth (%) Range
Min: -29.9   Max: 158.9
Current: 12.2

-29.9
158.9
EPS Growth (%) 10.90
SNTA's EPS Growth (%) is ranked higher than
81% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. SNTA: 10.90 )
SNTA' s 10-Year EPS Growth (%) Range
Min: -37.2   Max: 166.5
Current: 10.9

-37.2
166.5
» SNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SNTA Guru Trades in Q2 2013

Paul Tudor Jones 18,600 sh (New)
Steven Cohen 2,033,004 sh (+713.2%)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
» More
Q3 2013

SNTA Guru Trades in Q3 2013

Paul Tudor Jones Sold Out
Steven Cohen 2,005,800 sh (-1.34%)
» More
Q4 2013

SNTA Guru Trades in Q4 2013

Jim Simons 214,000 sh (New)
Louis Moore Bacon 115,000 sh (New)
Steven Cohen Sold Out
» More
Q1 2014

SNTA Guru Trades in Q1 2014

Murray Stahl 11,000 sh (New)
John Burbank 46,620 sh (New)
Louis Moore Bacon Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SNTA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-03-31 New Buy0.01%$4.28 - $7.01 $ 4.07-28%46620
Jean-Marie Eveillard 2012-06-30 Sold Out 0.0035%$3.68 - $7.82 $ 4.07-13%0
Jean-Marie Eveillard 2012-03-31 New Buy$4.22 - $5.66 $ 4.07-9%200000
Michael Price 2011-06-30 Sold Out 0.1%$4.45 - $6.23 $ 4.07-24%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.00
SNTA's P/B is ranked higher than
60% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. SNTA: 9.00 )
SNTA' s 10-Year P/B Range
Min: 2.91   Max: 38.2
Current: 9

2.91
38.2
EV-to-EBIT -3.53
SNTA's EV-to-EBIT is ranked lower than
59% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SNTA: -3.53 )
SNTA' s 10-Year EV-to-EBIT Range
Min: 0.6   Max: 2.2
Current: -3.53

0.6
2.2
Current Ratio 2.48
SNTA's Current Ratio is ranked higher than
67% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. SNTA: 2.48 )
SNTA' s 10-Year Current Ratio Range
Min: 0.43   Max: 7.01
Current: 2.48

0.43
7.01
Quick Ratio 2.48
SNTA's Quick Ratio is ranked higher than
70% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. SNTA: 2.48 )
SNTA' s 10-Year Quick Ratio Range
Min: 0.43   Max: 7.01
Current: 2.48

0.43
7.01

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.90
SNTA's Price/Net Cash is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SNTA: 9.90 )
SNTA' s 10-Year Price/Net Cash Range
Min: 3.46   Max: 80.9
Current: 9.9

3.46
80.9
Price/Net Current Asset Value 9.90
SNTA's Price/Net Current Asset Value is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SNTA: 9.90 )
SNTA' s 10-Year Price/Net Current Asset Value Range
Min: 3.46   Max: 80.9
Current: 9.9

3.46
80.9
Price/Tangible Book 9.00
SNTA's Price/Tangible Book is ranked higher than
67% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.20 vs. SNTA: 9.00 )
SNTA' s 10-Year Price/Tangible Book Range
Min: 3.07   Max: 30.05
Current: 9

3.07
30.05
Price/Median PS Value 1.00
SNTA's Price/Median PS Value is ranked lower than
52% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. SNTA: 1.00 )
SNTA' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 7.63
Current: 1

0.02
7.63
Forward Rate of Return (Yacktman) -12.13
SNTA's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.93 vs. SNTA: -12.13 )
SNTA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -48.2   Max: -17.2
Current: -12.13

-48.2
-17.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:YDO.Germany
Synta Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing & commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions like cancer and chronic inflammatory diseases.
» More Articles for SNTA

Headlines

Articles On GuruFocus.com
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 5,000 Shares Mar 15 2011 
Synta Pharmaceuticals Inc. (SNTA) VP, Fin. and Admin., CFO Keith S Ehrlich sells 2,537 Shares Mar 03 2011 
MAGIC FORMULA INVESTING 2010 YEAR IN REVIEW -- Winners: MGIC, QCOR, SNTA, CF; Losers: SPMD, JTX Jan 01 2011 
Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 10,000 Shares Jun 10 2010 
Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 22,222 Shares Jan 12 2010 
Synta Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2009 


More From Other Websites
Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with... Jul 21 2014
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 21 2014
Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with... Jul 21 2014
4:30 pm Synta Pharma announces advancement of Ganetespib into Phase 3 extension of AML LI-1 study... Jul 21 2014
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 18 2014
Synta Pharmaceuticals (SNTA) Shares March Higher, Can It Continue? Jul 08 2014
Synta Pharmaceuticals (SNTA) Jumps: Stock Rises 7.9% Jul 07 2014
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers Jun 27 2014
Synta Pharmaceuticals mentioned positively by The Street contributor Jun 24 2014
A Beaten-Down Biotech Stock Gearing Up for a Big Squeeze Higher Jun 24 2014
5-Star Biotech Stock Watch: Synta Pharmaceuticals Jun 18 2014
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 17 2014
Why A Short Covering Rally Might Come for Synta (SNTA) Stock Jun 16 2014
Five Biotech Stocks With Big Potential And Billionaire Believers Jun 16 2014
Synta to Present at the Jefferies 2014 Global Healthcare Conference May 29 2014
Synta Announces Presentations at the 2014 American Society for Clinical Oncology (ASCO) Annual... May 28 2014
Short Interest is Piling Up in Synta (SNTA) Stock, Time to Panic? May 23 2014
SYNTA PHARMACEUTICALS CORP Financials May 16 2014
5 Stocks Under $10 Set to Soar May 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide